ReviewInternational journal of molecular sciences2022
Clinicopathological and Molecular Features of Secondary Cancer (Metastasis) to the Thyroid and Advances in Management.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Proceedings of the 2026 North American Society of Head and Neck Pathology Companion Meeting, San Antonio, TX, March 22, 2026: It's a Trap! Pitfalls in Thyroid Pathology: Mets or Not Mets?Head and neck pathology · 2026Review
- Natural compounds naringin and nobiletin synergistically inhibit the PI3K/AKT/mTOR pathway in NSCLC: molecular docking and cytotoxicity studies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Plasma cells and plasmacytoid features in thyroid lesions.Virchows Archiv : an international journal of pathology · 2026Review
- Metastasis of lung adenocarcinoma to follicular thyroid carcinoma combined with papillary thyroid carcinoma in the contralateral lobe: A case report.Oncology letters · 2026Article
- Clear Cell Renal Cell Carcinoma Metastasis to the Thyroid: A Narrative Review of the Literature.Cancers · 2025Review
- A Rare Cause of Thyrotoxicosis: Metastasis of Ovarian Clear Cell Carcinoma to the Thyroid Gland.JCEM case reports · 2025Article
- Renal cell carcinoma metastasis to the thyroid gland after drug-induced thyroid dysfunction: case report.Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2025Article
- Machine Learning for Thyroid Cancer Detection, Presence of Metastasis, and Recurrence Predictions-A Scoping Review.Cancers · 2025Review
- Thyroid metastases from breast cancer: a case report and brief literature review.Frontiers in oncology · 2025Article
- Thyroid metastasis from ovarian clear cell carcinoma.Endocrinology, diabetes & metabolism case reports · 2024Article
- Ultrasonographic features and diagnostic accuracy of FNA and CNB in secondary thyroid malignancies: A retrospective study.Heliyon · 2024Article
- Thyroid gland: a rare site of metastasis.Endocrine · 2024Article
- Comparison and Analysis of Clinical Features of Papillary Thyroid Cancer Complicated With Hashimoto's Thyroiditis.Clinical Medicine Insights. Oncology · 2024Article
- Concomitant BRAF V600E and NRAS Q61R mutations in the same thyroid nodule: a case report.AME case reports · 2024Article
- Metastatic Disease to a Concurrent Thyroid Neoplasm: A Case Series and Review of the Literature.Head and neck pathology · 2023Review
- Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma.Iranian journal of public health · 2023Article
- Neuroendocrine neoplasm with metastasis to the thyroid: a case report and literature review.Frontiers in oncology · 2023Article
- Recent Advances in Thyroid Cancer Research.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary tumours to the thyroid gland are uncommon and often incidentally discovered on imaging. Symptomatic patients often present with a neck mass. Collision tumours of secondary tumours and primary thyroid neoplasms do occur. Ultrasound-guided fine-needle aspiration, core-needle biopsy, and surgical resection with histological and immunohistochemical analysis are employed to confirm diagnosis as well as for applying molecular studies to identify candidates for targeted therapy. Biopsy at the metastatic site can identify mutations (such as EGFR, K-Ras, VHL) and translocations (such as EML4-ALK fusion) important in planning target therapies. Patients with advanced-stage primary cancers, widespread dissemination, or unknown primary origin often have a poor prognosis. Those with isolated metastasis to the thyroid have better survival outcomes and are more likely to undergo thyroid resection. Systemic therapies, such as chemotherapy and hormonal therapy, are often used as adjuvant treatment post-operatively or in patients with disseminated disease. New targeted therapies, such as tyrosine kinase inhibitors and immune checkpoint inhibitors, have shown success in reported cases. A tailored treatment plan based on primary tumour features, overall cancer burden, and co-morbidities is imperative. To conclude, secondary cancer to the thyroid is uncommon, and awareness of the updates on diagnosis and management is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.